Alert | Azithromycin in the newborn period increases the risk of developing pyloric stenosis.\textsuperscript{14-15}

| Indication | 1. Pertussis – post-exposure prophylaxis and treatment  
| | 2. Neonatal chlamydial conjunctivitis and pneumonia  
| | 3. Chlamydia and *Mycoplasma* pneumonia \(\geq 3\) months of age  
| | 4. Eradication of *Ureaplasma* in preterm infants  
| | 5. Prevention of BPD in preterm neonates – routine use is not recommended.

Action | Azithromycin inhibits protein synthesis by attaching to the 50S subunit of the bacterial ribosome in susceptible organisms. It exhibits bacteriostatic activity with higher potency than erythromycin against *Ureaplasma* isolates in vitro. Azithromycin inhibits neutrophil influx and chemoattractant/cytokine release in murine lung non-infectious, as well as pneumonia, injury models. It is preferentially concentrated in pulmonary epithelial lining fluid and alveolar macrophages.\textsuperscript{14}

Drug Type | Macrolide antibiotic (subclass Azalide)

Trade Name | Azith, Azithromycin Alphapharm, Azithromycin DBL, Zithromax

Presentation
Oral: 200 mg/5 mL (15 mL) suspension, 500 mg tablet
IV: 500 mg vial

Dosage/Interval

| Pertussis (post-exposure prophylaxis or treatment) | 10 mg/kg/dose daily orally or IV\textsuperscript{2} for 5 days. |
| Treatment of neonatal chlamydial conjunctivitis and pneumonia | 20 mg/kg/dose daily orally for 3 days. |
| Eradication of *Ureaplasma* in preterm infants | 20 mg/kg/dose daily IV for 3 days. |
| Pneumonia due to *Chlamydia* or *Mycoplasma pneumoniae* \(\geq 3\) months of age | Initial therapy or therapy for serious infection: 10 mg/kg/dose IV once a day on days 1 and 2, followed by oral therapy if needed.  
Step-down or Mild therapy: 10 mg/kg ORALLY on day 1, followed by 5 mg/kg once daily on days 2–5. |

Route | Oral  
| | IV

Maximum Daily Dose | 20 mg/kg

Preparation/Dilution

**Oral:** Add 9 mL of sterile water. Cap and shake well to produce 15 mL of suspension. Suspension expires 10 days after reconstitution. Write expiry date on bottle.

**IV:** Add 4.8 mL of water for injection to the vial to make a concentration of 100 mg/mL solution. Shake until dissolved. Add 1 mL of reconstituted solution to 49 mL of sodium chloride 0.9% to make a concentration of 2 mg/mL and infuse over 1–3 hours. Maximum concentration for infusion is 2 mg/mL.

Administration

**Oral:** Shake well before use. May be given with or without feed.

**IV:** Infuse over at least 1 hour.

Monitoring

During infusion – heart rate and blood pressure.  
IV site for signs of phlebitis.  
Liver function.

Contraindications
Hepatic dysfunction with prior azithromycin therapy.  
Concomitant therapy with QT interval prolonging drugs (e.g. cisapride)

Precautions
Hepatic dysfunction.  
IV solutions of a concentration greater than 2 mg/mL may cause local infusion-site reactions.

Drug Interactions
Drugs that can prolong QT interval.  
Digoxin – may result in digoxin toxicity.
| Adverse Reactions | Common: Nausea, vomiting, abdominal pain and diarrhoea (all less than erythromycin).
Rare: Hypertrophic pyloric stenosis, thrombophlebitis (after IV administration), ventricular dysrhythmias (after IV administration). In general, the risk of dysrhythmias is increased when these agents are administered in combination with other drugs that prolong the QT interval. Increased liver enzymes, hepatitis, hepatic necrosis, hypersensitivity reactions. |
| Compatibility | Fluids: Glucose 5%, glucose 5% in sodium chloride solutions, Hartmann’s, sodium chloride 0.9%, sodium chloride 0.45%  
Y-site: Bivalirudin, ceftaroline fosamil, dexmedetomidine, tigecycline |
| Incompatibility | Fluids: No information  
Drugs: Amikacin, amiodarone, aztreonam, cefotaxime, ceftazidime, ceftriaxone, chlorpromazine, ciprofloxacin, clindamycin, fentanyl, furosemide (frusemide), gentamicin, imipenem-cilastatin, ketorolac, midazolam, morphine sulfate, mycophenolate mofetil, pentamidine, piperacillin-tazobactam (EDTA-free), potassium chloride, thiopental sodium, ticarcillin-clavulanate, tobramycin. |
| Stability | Oral suspension: After reconstitution, the suspension should be stored below 30 °C and any remaining suspension discarded after 10 days.  
Reconstituted IV solution: Stable for 24 hours at ≤30 °C. |
| Storage | Oral/IV store below 25 °C. Protect from light. |
| Special Comments | Refer to full version. |
| Evidence summary | Refer to full version. |
| References | Refer to full version. |

Original version Date: 20/06/2018  
Author: Neonatal Medicines Formulary Group  
Current Version number: 1.0  
Version Date: 20/06/2018  
Risk Rating: Medium  
Due for Review: 20/06/2021  
Approval by:  
Approval Date:  

Authors Contribution
- Original author/s: Chris Wake, Srinivas Bolisetty  
- Revision author/s: Tony Lai, Brendan McMullan  
- Expert review: David Osborn  
- Evidence Review: Eszter Jozsa, Robyn Richards  
- Nursing Review: Jing Xiao, Carmen Burman, Cindy Chen  
- Pharmacy Review: Nilkant Phad, Himanshu Popat, Michael Hewson, Jessica Ryan, Joanne Patel, Roland Broadbent  
- Final content and editing review of the original: Ian Whyte  
- Electronic version: Cindy Chen, Ian Callander  
- Facilitator: Srinivas Bolisetty